Brokerages predict that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) will report $5.83 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $9.17 million. The business is scheduled to report its next earnings results on Monday, January […]
Wall Street analysts expect PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) to post sales of $5.83 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $9.17 million. The firm is […]
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) announced its earnings results on Thursday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.31), MarketWatch Earnings reports. PHAS stock opened at $1.14 on Friday. The business has a 50 day simple moving average of $1.46 and a 200-day simple moving average […]